Alterações cogntivas e neuroquimicas pelo uso crônico de monoterapia e terapia combinada de antidepressivos em ratos

• Autor(a) principal: Menezes, Carlos Eduardo de Souza
• Data de Publicação: 2012
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
• Texto Completo: http://www.repositorio.ufc.br/handle/riufc/5372
• topic: Antidepressivos; Terapêutica

Depression is a chronic and recurrent psychopathological condition, with obvious socio-occupational injury and quality of life in both the acute and long term. Depression is caused by afunctional deficit of monoamines in their signaling pathways (serotoninergic, dopaminergic, noradrenergic) in certain parts of the brain. Although there are various forms of clinical treatment of mood disorders such as psychotherapy, antidepressants, ECT and TMS, the prescription of antidepressant drugs is the main form of management of calls endogenous depressions. The functional modulation of neurochemical transmission paths can interfere with the processing performance of cognitive functions like memory. Objective: Our study sought to investigate the possible changes in different types and stages of memory caused by chronic use of antidepressants from different managements; monotherapy and combination therapy. Methods: We use this research to chronic administration of three antidepressant drugs and their associations (paroxetine, venlafaxine and bupropion) widely used in clinical practice. To evaluate the performance mnemonic to use behavioral models predictive of mice with eigen value memory (radial maze, passive avoidance) and exploratory activity (open field). They measured levels of BDNF and AChE in the hippocampus of rats in groups of antidepressant users. Results: Radial Maze - acquisition phase: the Venlaf group (11 ±4.85), associated with Venlaf Parox (10,88±5,30) associated with Buprop and Venlaf (11 ± 3.85) showed a number of training trials significantly higher compared to that of the control group (5.11± 1.36), while groups with Parox (4, 14 ± 2.19), Buprop (7.1 ± 3.66) associated with Parox alone and Buprop (4.75 ± 1.75) showed no change in the number of significant attempts. Radial Maze - MC: Venlaf groups (2.16 ±1.47) associated with Venlaf Parox (2.85 ± 1.35) associated with Buprop and Venlaf (2.62 ± 1.76) showed no significant changes compared to the user group of saline (2.25 ± 1.58) while users of antidepressants Parox (3.11 ± 1.69), Buprop (4.9± 2.99) associated with Buprop and Parox (4.12 ± 2.58) had significantly (p <0.001) greater errors in the control group (2.25 ± 1.58). Radial Maze – ML: Venlaf users groups (4.5 ± 1.64), Buprop (4 ± 2.3) associated with Buprop and Venlaf (2.87 ± 1.72) showed no significant than the control group (3.11 ± 1.36),where as the group user Parox (4.4± 1.50) howed a significantly greater errors in the control group (3.11 ± 1 ,36) Venlaf users groups associated with Parox (2.66 ± 0.85) associated with Buprop and Parox (3.12 ± 2.16) had a number of errors significantly lower when compared to the number of errors in Paroxetine (4.4 ± 1.50). Avoidance passive –MC and ML : Parox users groups(218.4 ± 113.1) Buprop (39.57 ± 23.19) and associated with Parox Buprop (300 ± 0.0) showed a significant lag time higher in the control group (270 ± 37.30). ML: Venlaf users groups associated with Parox (218.1 ± 103.6) associated with Buprop and Parox (296.7 ± 8.69) revert the increase in the latency time of the Parox (218,1±103,6) and caused a significant decrease the time spent in the compartment of the mouse course over the same group. Open Field: Parox (20.80 ± 3.85) increased significantly in the control (14.90 ± 3.85) while the user group Buprop associated with Parox (12 ± 2.50) reversed the increase in locomotor activity of the Parox group (20.80 ± 3.85). Conclusions: the test of acquisition show loss of performance in groups o antidepressant users with little selectivity for serotonin reuptake. The MC and ML in visual-spatial skills, we found deficits in groups of antidepressants that potentiate both serotonin action with dopaminergic action. The potentiation of β-adrenergic is associated with increased level of alertness and improves the performance of establishment and consolidation of MC and ML.